Healio Healio News
All Specialties Aesthetics Allergy/Asthma Cardiac/Vascular Intervention Cardiology Dermatology Endocrinology Gastroenterology Hematology/Oncology Hepatology Infectious Disease Nephrology Neurology Ophthalmology Optometry Orthopedics Pediatrics Primary Care Psychiatry Pulmonology Rheumatology Women's Health & OB/GYN
All Subspecialties Arrhythmia Disorders CHD/Prevention Diabetes Genetics/Genomics HF/Transplantation Imaging Intervention Pediatric Cardiology Practice Management Stroke Surgery Vascular Medicine
Trial Scorecards

Trial Scorecards
Issue: July 2013
July 01, 2013
1 min read
Save

VIVIDD

Issue: July 2013
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Researchers investigated the effects of vildagliptin in patients with type 2 diabetes and HF with reduced ejection fraction.

VIVIDD 
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Trial Scorecards

Trial Scorecards

MORE FROM THIS COLLECTION

Related Content